Cidara Therapeutics, Inc.
CDTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.07 | 0.04 | 0.03 |
| FCF Yield | -103.51% | -33.04% | -54.10% | -37.96% |
| EV / EBITDA | 0.09 | -1.58 | -0.64 | -0.22 |
| Quality | ||||
| ROIC | -105.52% | -2,737.42% | -393.76% | -96.99% |
| Gross Margin | -6,557.49% | 97.62% | 99.78% | 99.62% |
| Cash Conversion Ratio | 1.04 | 0.98 | 0.85 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -72.95% | -22.27% | 74.80% | 33.33% |
| Free Cash Flow Growth | -670.21% | 19.78% | -13.13% | 53.71% |
| Safety | ||||
| Net Debt / EBITDA | 1.06 | 1.27 | 0.94 | 1.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -199.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.25 | 0.00 | -0.07 |
| Cash Conversion Cycle | 469.43 | 650.00 | -3,660.27 | -7,480.72 |